IBC-01-01 Clinical Trial

ImmunoBrain has completed IBC-01-01, a Phase 1b clinical trial investigating ImmunoBrain’s IBC-Ab002 in patients with early Alzheimer’s disease.

IBC-01-01 was a randomized, double-blind, placebo-controlled, first-in-human Phase 1b clinical trial designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory markers of efficacy of IBC-Ab002 in participants with early Alzheimer’s disease.

The trial enrolled 40 participants with early Alzheimer’s disease across five dose cohorts, using a seamless single ascending dose to multiple ascending dose (SAD/MAD) design, with four IV infusions administered over approximately 48 weeks. The study was conducted across sites in the U.K., Israel, and the Netherlands.

Topline results demonstrated a favorable safety and tolerability profile, along with evidence of target engagement. Disease-related CSF biomarker analysis (Neurogranin, total-Tau, and pTau181) in patients treated with 30 mg/kg IBC-Ab002, compared to placebo, showed directionally favorable changes, supporting further clinical development.

IBC-01-01 is supported in part by grants from the National Institute on Aging (NIA) and the Alzheimer’s Association.

For more information please visit https://clinicaltrials.gov/study/NCT05551741 or reach out to us at info@immunobrain.com